Skip to main content
. 2018 Aug 21;14(12):2083–2103. doi: 10.1080/15548627.2018.1503146

Figure 1.

Figure 1.

RNA-binding protein ELAVL1 expression is increased during HSC ferroptosis. HSC-LX2 and HSC-T6 cells were treated with erastin (10 μM), BSO (200 μM), and sorafenib (5 μM) with or without the indicated inhibitors (ZVAD-FMK, 10 μM; ferrostatin-1, 1 μM; necrosulfonamide, 0.5 μM) for 24 h. (a) Cell viability and (b) MDA levels were assayed (n = 3 in every group, **, p < 0.01). HSC-LX2 and HSC-T6 cells were treated with erastin (10 μM), BSO (200 μM), and sorafenib (10 μM) for 24 h. (c) ELAVL1 protein and (d) mRNA levels were determined (n = 3 in every group). (e) HSC-LX2 cells were treated with erastin (10 μM) with or without MG-132 (5 μM) or cycloheximide (CHX, 20 μg/ml) for 24 h, and ELAVL1 protein level was assayed (n = 3 in every group, **, p < 0.01, ***, p < 0.001, #, p < 0.05). (f) HSC-LX2 cells were treated with CHX (20 μg/ml) for 1 h or treated with erastin (10 μM) for 4 h followed by CHX (20 μg/ml) for 1 h. ELAVL1 protein level was determined at the indicated time points (n = 3 in every group).